Drugs / Autologous Bone Marrow-Derived Mononuclear Stem Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02587806 | Feb 2015 → Feb 2017 | relapsing-remitting multiple sclerosis | Novo Cellular Medicine Institute LLP | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Bone Marrow-Derived Mononuclear Stem Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02587806 ↗ |
| Known as | BM-MNC | “Super selective intravenous administration of 50 million Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC)” NCT02587806 ↗ |